Patent intelligence · US
US 10215762
Method to optimize the treatment of patients with biological drugs
Method to optimize the treatment of patients with biological drugs
Patent details — US 10215762
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 26, 2019
- Expiration
- Feb 21, 2039
- Applicant
- PROGENIKA BIOPHARMA, S.A.
- Claims
- 11
- CPC classes
- A61K, A61K39/3955, A61K49/00
Quick answer
US 10215762 (Method to optimize the treatment of patients with biological drugs) is held by PROGENIKA BIOPHARMA, S.A.. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PROGENIKA BIOPHARMA, S.A.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K39/3955, A61K49/00
More from PROGENIKA BIOPHARMA, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 10215762?
US 10215762 (Method to optimize the treatment of patients with biological drugs) is held by PROGENIKA BIOPHARMA, S.A.. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10215762?
PROGENIKA BIOPHARMA, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 10215762 expire?
Our index shows an expiration date of Feb 21, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.